Company Profile

Cogent Biosciences Stock Price, News & Catalysts

Ticker:
COGT
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

27.74 USD (-0.25%)

Close

Last updated: November 19, 2026

5.6B USD

Market cap

Why the stock is moving

As of Nov 19, 2026, COGT closed down 0.25% at $27.74. No new same-company headline was identified in the current news window.

Company overview

Genetically Defined Diseases

Cogent Biosciences develops precision therapies for diseases driven by defined oncogenic mutations. Its portfolio is led by a selective KIT inhibitor and includes earlier programs directed at ErbB2, PI3Kα, KRAS and JAK2.

Bezuclastinib

Bezuclastinib is designed to inhibit KIT D816V and other exon 17 KIT mutations while limiting off-target activity. These mutations drive systemic mastocytosis and are also important resistance mechanisms in gastrointestinal stromal tumors.

Systemic Mastocytosis Franchise

The company is pursuing bezuclastinib in both non-advanced and advanced systemic mastocytosis. An NDA for non-advanced disease is under FDA review, while the APEX program supports a separate planned application in advanced disease.

Gastrointestinal Stromal Tumors

The Phase 3 PEAK trial supports an NDA for bezuclastinib in GIST after prior imatinib treatment. Cogent also plans to study bezuclastinib with sunitinib in first-line exon 9-mutant GIST, potentially extending use into an earlier treatment setting.

Early Precision-Oncology Pipeline

CGT4255 is a brain-penetrant ErbB2 inhibitor and CGT6297 is a selective PI3Kα inhibitor, both in Phase 1 studies. Preclinical candidates CGT1815 and CGT1145 target pan-KRAS(ON) and JAK2 V617F, respectively.

Future catalysts

  • FDA action on bezuclastinib in gastrointestinal stromal tumors on November 30, 2026.
  • FDA action on bezuclastinib in non-advanced systemic mastocytosis on December 30, 2026.
  • First clinical results from the SUMMIT avapritinib-switch sub-study at ASH in December 2026.
  • IND submissions for CGT1815 and CGT1145 in the fourth quarter of 2026.
  • FDA action on bezuclastinib in advanced systemic mastocytosis on June 29, 2027.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of Cogent Biosciences (COGT)?

Cogent Biosciences (COGT) most recently closed at 27.74 USD, a -0.25% move versus the previous session.

What is the market cap of Cogent Biosciences (COGT)?

Cogent Biosciences currently has a market capitalization of 5.6B USD on BioPharmSignal.

What does Cogent Biosciences do?

Genetically Defined Diseases Cogent Biosciences develops precision therapies for diseases driven by defined oncogenic mutations. Its portfolio is led by a selective KIT inhibitor and includes earlier programs directed at ErbB2, PI3Kα, KRAS and JAK2. Bezuclastinib Bezuclastinib is designed to inhibit KIT D816V and other exon 17 KIT mutations while limiting...

On which exchange is COGT stock listed?

Cogent Biosciences (COGT) is associated with NASDAQ, United States, Biopharma.

What is bezuclastinib?

FDA action on bezuclastinib in gastrointestinal stromal tumors on November 30, 2026.

Which conditions is Cogent Biosciences targeting with bezuclastinib?

Cogent Biosciences is associated with oncology, genetic disease based on its company overview and current catalyst commentary.

How does Cogent Biosciences describe recent progress with bezuclastinib?

FDA action on bezuclastinib in gastrointestinal stromal tumors on November 30, 2026.

What is imatinib?

Gastrointestinal Stromal Tumors The Phase 3 PEAK trial supports an NDA for bezuclastinib in GIST after prior imatinib treatment.